作者
A Takeda, E Loveman, A Clegg, J Kirby, J Picot, E Payne, C Green
发表日期
2006/1
来源
International Journal of Geriatric Psychiatry: A journal of the psychiatry of late life and allied sciences
卷号
21
期号
1
页码范围
17-28
出版商
John Wiley & Sons, Ltd.
简介
Background
The use of cholinesterase inhibiors for Alzheimer's disease (AD) is currently being appraised by the National Institute for Clintical Evidence (NICE). This article provides the latest evidence that NICE will be using as part of this appraisal process.
Objective
To provide a systematic review of the best quality evidence of the effects of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in people with mild to moderately‐severe AD.
Design
Electronic databases were searched, references of all retrieved articles were checked, and experts were contacted for advice, peer review and to identify additional references. Randomised controlled trials (RCTs) were included if they fulfilled pre‐specified criteria. Data were synthesised through a narrative review.
Results
Twenty‐six RCTs that compared any one of the cholinesterase inhibitors with either a control group or with …
引用总数
学术搜索中的文章
A Takeda, E Loveman, A Clegg, J Kirby, J Picot… - International Journal of Geriatric Psychiatry: A journal …, 2006